Day One Biopharmaceuticals, Inc.
dayonebio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2025 10-K, filed Feb 24, 2026. Its latest SEC filing is a SCHEDULE 13G/A from May 15, 2026.
10-K for FY2025, filed Feb 24, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Sells OJEMDA for children with relapsed or refractory pediatric low-grade glioma and develops targeted cancer medicines for people with other serious diseases.
10-K for FY2025, filed Feb 24, 2026Day One Biopharmaceuticals, Inc., or the Company or Day One, is a biopharmaceutical company dedicated to developing and commercializing…View ↗
On April 23, 2024, we announced that the FDA approved OJEMDA™ (tovorafenib) for the treatment of patients 6 months of age and older with…View ↗
In June 2024, we entered into a license agreement, or the MabCare License Agreement, with MabCare Therapeutics, or MabCare, a…View ↗
Emi-Le, XMT-1660, is an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a…View ↗
How Did They Make Money?
Specialty pharmacies and distributors pay for OJEMDA when it is delivered. Ipsen paid an upfront fee for rights outside the United States, with additional milestone and royalty payments linked to launches and sales.
10-K for FY2025, filed Feb 24, 2026The Company recognizes net product revenue from OJEMDA for the treatment of patients 6 months of age and older with relapsed or refractory…View ↗
The Company has determined that the delivery of OJEMDA to its customers constitutes a single performance obligation. There are no other…View ↗
The Company generates license revenue from the Ipsen License Agreement, pursuant to which, the Company licensed to Ipsen Pharma SAS, or…View ↗
Under the terms of the Ipsen License Agreement, (i) Ipsen paid the Company an upfront license fee in the amount of $70.8 million and (ii)…View ↗
The commercial launch milestones related to first commercial sale(s) in certain territories, sales-based milestones and royalties are…View ↗
$158.2M
-
10-K for FY2025, filed Feb 24, 2026
$158.2M ↗
Who Were Their Customers?
U.S. specialty pharmacies and distributors buy OJEMDA through contracts with Day One.
10-K for FY2025, filed Feb 24, 2026
10-K for FY2025, filed Feb 24, 2026
For the year ended December 31, 2025, two individual customers accounted for 97.6% of total net product revenue, with these individual…View ↗
How Were They Changing?
-
Apr 23, 2026
Servier completed its acquisition of Day One
Servier acquired all voting securities, and Day One requested that Nasdaq delist its shares.
Sources
8-K, filed Apr 23, 2026
As a result of the consummation of the Offer and the Merger, there was a change in control of the Company, and Parent, as the direct parent…View ↗
Who Did They Compete With?
Competes with Genentech, Novartis, Pfizer, Fore Biotherapeutics, Black Diamond Therapeutics, Jazz Pharmaceuticals, Redx Pharma, Erasca, Nested Therapeutics, Profound Bio, Genmab, Sichuan Kelun Pharmaceutical Research Institute, Eli Lilly and, Whitehawk, IDEAYA, Biocytogen, Kivu Bio, Zymeworks, and SutroBio
10-K for FY2025, filed Feb 24, 2026Three BRAF inhibitors have been approved by the FDA for the treatment of tumors containing V600E or V600K mutations. These first-generation…View ↗
Loading...
